Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Psoriasis Clinical Trial

— BeNeBio  

Official title:

Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04340076
• Other study ID #: 80-85200-98-18562
• Secondary ID: 2019-004230-42
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: August 20, 2020
• Est. completion date: December 2025

Study information

• Verified date: September 2023
• Source: Radboud University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients. Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be carried out.

Description:

Rationale: Biologics are very effective treatments for psoriasis. Research indicated that the dose of TNFα-blocking biologics can be reduced in a proportion of patients. Safety profiles can improve and costs can be reduced if the reduction of the dose is successful. Recently, the newest generation of biologics entered the market: interleukin (IL) 17 and IL23 inhibitors. It is not yet known whether dose reduction of these agents is possible, and to what extent they can be reduced. The timely investigation of the possibilities for dose reduction of new biologics is therefore important.

Objectives: The primary goal is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care. This is measured by comparing the proportion of long-term disease flares between the two groups (dose reduction group versus usual care group). Secondary goals are: determining the proportion of patients with successful dose reduction, clinical effectiveness measured with the Psoriasis Area and Severity score (PASI) score, Dermatology Life Quality Index (DLQI) scores, predictors for successful dose reduction, safety, and cost-effectiveness of dose reduction. Pharmacokinetic (PK) analysis will be performed for modeling.

Study design: a multicenter, practice-oriented, pragmatic, randomized, controlled, non-inferiority study.

Study population: Patients treated with the newest generation of biologics (IL17 or IL23 inhibitors), with long-term stable low disease activity at a normal dose. A total of 244 patients will be randomized (2:1) to dose reduction or continuation of usual care.

Intervention: Dose reduction by interval prolongation in 2 steps to a maximum decrease of 50% of the original dose when disease activity (PASI) and quality of life index (DLQI) remain low.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 244
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Plaque psoriasis (primarily)

• Treatment for at least 6 months with IL23 or IL17 inhibitor in a normal dose (dose advised by the label)

• PASI= 5 at inclusion and in previous 6 months (if no PASI scores are available, it should be clear from the patient record that psoriasis was clear/almost clear in previous 6 months).

• DLQI = 5 at inclusion

Exclusion Criteria:

• Another indication than plaque psoriasis as the main indication for biologic use (e.g. patient receives biologic for rheumatoid arthritis as the main indication).

• Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc).

• Severe comorbidities with short life-expectancy (e.g. metastasized tumor).

• Presumed inability to follow the study protocol.

Related Conditions & MeSH terms

• Psoriasis
• Psoriasis Vulgaris

Intervention

Drug:
• Secukinumab
Maintenance/normal dose is 300 mg/4 weeks. First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks.
• Ixekizumab
Maintenance/normal dose is 80 mg/4 weeks. First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks
• Brodalumab
Maintenance/normal dose is 210 mg/2 weeks. First dose reduction step: 210 mg/3 weeks. Second dose reduction step: 210 mg/4 weeks.
• Guselkumab
Maintenance/normal dose is 100 mg/8 weeks. First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks.
• Risankizumab
Maintenance/normal dose is 150 mg every 12 weeks. First dose reduction step: 150mg/18 weeks. Second dose reduction step: 150mg/24 weeks.
• Tildrakizumab
Maintenance/normal dose is 100 mg or 200 mg every 12 weeks. First dose reduction step: 100 mg or 200 mg/18 weeks. Second dose reduction step: 100 mg or 200 mg/24 weeks.
• Bimekizumab
Maintenance/normal dose is 320 mg/8 weeks. First dose reduction step: 320 mg/12 weeks. Second dose reduction step: 320 mg/16 weeks.

Locations

Country	Name	City	State
Belgium	ULB Erasme	Brussels
Belgium	Ghent University Hospital	Gent
Belgium	AZ Maria Middelares	Ghent
Belgium	AZ St Lucas	Ghent
Belgium	UZ Leuven	Leuven
Belgium	CHU Liege	Liège
Belgium	UCL Saint Luc	Louvain
Belgium	Dermatologie Maldegem	Maldegem
Netherlands	Ziekenhuisgroep Twente	Almelo
Netherlands	Bravis hospital	Bergen Op Zoom
Netherlands	Amphia Hospital	Breda
Netherlands	Slingeland hospital	Doetinchem
Netherlands	Catharina hospital	Eindhoven
Netherlands	UMC Groningen	Groningen
Netherlands	Maastricht UMC	Maastricht
Netherlands	Radboudumc	Nijmegen
Netherlands	Erasmus MC	Rotterdam
Netherlands	UMC Utrecht	Utrecht
Netherlands	Máxima Medisch Centrum	Veldhoven

Sponsors (4)

Lead Sponsor	Collaborator
Radboud University Medical Center	Belgium Health Care Knowledge Centre, University Hospital, Ghent, ZonMw: The Netherlands Organisation for Health Research and Development

Countries where clinical trial is conducted

Belgium,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Non-inferiority of the incidence proportion of persistent flares (Psoriasis Area and Severity Index (PASI) >5 for = 3 months).		18 months
Secondary	Whether participants will have successful DR after 12 and 18 months, defined as using a lower dose than the normal dose and PASI = 5.	Definition of successful dose reduction: lower dose than the normal dose and PASI= 5.	18 months
Secondary	Psoriasis disease activity, measured with the Psoriasis Area and Severity Index (PASI) at each 3-monthly study visit.		18 months
Secondary	Dermatology-related quality of life as measured with the Dermatology Life Quality Index (DLQI) at each 3-montly study visit.		18 months
Secondary	Whether participants will have short disease flares throughout the study period (18 months), defined as a PASI > 5 at one time point.		18 months
Secondary	Whether other anti-psoriatic medication will be initiated in participants during the study period (18 months).		18 months
Secondary	Whether participants will have serious adverse events (SAE) and adverse events of special interest (AEoSI) during the study period.	AEoSI include, but are not limited to, infections, malignancies, and joint complaints or new-onset psoriatic arthritis.	18 months
Secondary	Drug trough levels of each included drug, measured in blood serum samples which will be collected from participants at each 3-montly time point.		18 months
Secondary	Anti-drug antibody levels of each included drug, measured in blood serum samples which will be collected from participants at each 3-montly time point.		18 months
Secondary	Utilities, derived from EuroQoL 5 Dimensions (EQ-5D-5L) questionnaires, which will be measured at each 3-montly time point.	Utility scores will be used to calculate quality adjusted life years (QALYs) which are used to determine cost-effectiveness of DR.	18 months
Secondary	Health status of participants, assessed by using the Short Form 36 (SF-36) version 2 questionnaire at every 3-monthly time point.		18 months
Secondary	Volumes of care, as measured with the iMTA Medical Consumption Questionnaire (MCQ) at each 3-monthly time point. Scores will be used to calculate direct medicals costs and non-medical costs.		18 months
Secondary	Loss of productivity and presenteeism of participants, as measured with the iMTA Productivity Cost Questionnaire (PCQ) at each 3-monthly time point. Scores will be used to calculate direct medicals costs and non-medical costs.		18 months